Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer

NCT04744831 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

122

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Colorectal Cancer

Interventions

DRUG: DS-8201a 5.4 mg/kg Q3W
DRUG: DS-8201a 6.4 mg/kg Q3W

Sponsor

Daiichi Sankyo

Collaborators

[object Object]